Guardant Health Inc GH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval
-
FDA Approves AstraZeneca Treatment for Advanced Breast Cancer — Update
-
A new blood test can help detect colon cancer, but it's not as good as the test you hate to take
-
These 15 stocks are still showing momentum - and a market-beating edge
Trading Information
- Previous Close Price
- MX$2,784.00
- Day Range
- MX$2,784.00–2,784.00
- 52-Week Range
- MX$820.00–2,784.00
- Bid/Ask
- MX$2,784.00 / MX$2,784.00
- Shares Outstanding
- 134.20M
- Market Cap
- $373.60B
- Volume/Avg
- 10 / 27
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.92
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 2,506
- Website
- https://www.guardanthealth.com
Competitors
Valuation
|
Metric
|
GH
|
ILMN
|
|---|---|---|
Price/Earnings (Normalized) | — | 54.01 |
Price/Book Value | — | 14.80 |
Price/Sales | 16.92 | 9.53 |
Price/Cash Flow | — | 33.03 |
Price/Earnings
GH
ILMN
Financial Strength
|
Metric
|
GH
|
ILMN
|
|---|---|---|
Quick Ratio | 3.53 | 1.22 |
Current Ratio | 4.03 | 1.80 |
Interest Coverage | −101.42 | 10.96 |
Quick Ratio
GH
ILMN
Profitability
|
Metric
|
GH
|
ILMN
|
|---|---|---|
Return on Assets (Normalized) | −13.43% | 6.73% |
Return on Equity (Normalized) | — | 16.79% |
Return on Invested Capital (Normalized) | −19.73% | 9.37% |
Return on Assets
GH
ILMN
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|TxgP?#Z | LOCK|^p | $243B | |||
| Danaher Corp
DHR
| LOCK|VpS#wF@C | LOCK|q!N | $155B | |||
| Agilent Technologies Inc
A
| LOCK|tfSsMN$> | LOCK|CR | $48B | |||
| IQVIA Holdings Inc
IQV
| LOCK|nyd%>zg | LOCK|<VWs | $43B | |||
| Waters Corp
WAT
| LOCK|Gw<<?R! | LOCK|@> | $43B | |||
| Illumina Inc
ILMN
| LOCK|x^rH<#$ | LOCK|NQ%%^ | $42B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|d?JJ&p@ | LOCK|@> | $41B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|kHt%R$N | LOCK|#^wd | $31B | |||
| Quest Diagnostics Inc
DGX
| LOCK|ZNjTQ?< | LOCK|wLrY< | $25B | |||
| Labcorp Holdings Inc
LH
| LOCK|#f%%h$%$ | LOCK|m>>^@ | $25B |
United States